专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011105735A Inhibitor of protein tyrosine kinase activity 有权
标题翻译：蛋白酪氨酸激酶活性的抑制剂
公开(公告)号：JP2011105735A
公开(公告)日：2011-06-02
申请号：JP2011010326
申请日：2011-01-21
申请人： Methylgene Inc , メチルジーンインコーポレイテッド
发明人： MANNION MICHAEL , RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , GAUDETTE FREDERIC , ZHAN LIJIE , ISAKOVIC LJUBOMIR , SAAVEDRA OSCAR MARIO , UNO TETSUYUKI , KISHIDA MASASHI , VAISBURG ARKADII
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/5377 , A61P9/00 , A61P11/00 , A61P11/02 , A61P17/00 , A61P27/02 , A61P27/16 , A61P35/00 , A61P35/02 , A61P43/00
CPC分类号： C07D495/04 , C07F9/6561
摘要： PROBLEM TO BE SOLVED: To provide a compound for inhibiting protein tyrosine kinase activity; in particular, to provide a compound, a composition and a method, each for treating cell proliferative diseases and conditions and ophthalmologic diseases, disorders and conditions. SOLUTION: This invention relates to a compound represented by a formula as indicated, its hydrate, its solvate, its pharmaceutically allowable salt, its prodrug, its complex, a racemic and scalemic mixture, its diastereomer and its enantiomer. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：待解决的问题：提供抑制蛋白酪氨酸激酶活性的化合物; 特别地，提供用于治疗细胞增殖性疾病和病症以及眼科疾病，病症和病症的化合物，组合物和方法。本发明涉及由所示的式表示的化合物，其水合物，其溶剂化物，其药学上可允许的盐，其前药，其络合物，外消旋和可比混合物，其非对映异构体及其对映异构体。版权所有（C）2011，JPO＆INPIT

2. 发明申请

WO2008035209A3 QUINOLINE AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY 审中-公开
标题翻译：喹啉和喹唑啉衍生物作为蛋白酪氨酸激酶活性的抑制剂
公开(公告)号：WO2008035209A3
公开(公告)日：2011-03-03
申请号：PCT/IB2007003264
申请日：2007-05-30
申请人： METHYLGENE INC , RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , SAAVEDRA OSCAR MARIO , VAISBURG ARKADII , DEZIEL ROBERT , ZHAN LIJIE , MANNION MICHAEL , GAUDETTE FREDERIC , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
发明人： RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , SAAVEDRA OSCAR MARIO , VAISBURG ARKADII , DEZIEL ROBERT , ZHAN LIJIE , MANNION MICHAEL , GAUDETTE FREDERIC , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
IPC分类号： C07D401/12 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/12 , C07D413/14
CPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C12N9/1205
摘要： The invention relates to quinoline and qumazoline derivatives that inhibit protein tyrosine kinase activity In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling The invention also provides compositions and methods for treating cell proliferative diseases and conditions
摘要翻译：本发明涉及抑制蛋白酪氨酸激酶活性的喹啉和喹唑啉衍生物。具体地，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如VEGF受体信号传导的抑制和 HGF受体信号传导更具体地，本发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物，组合物和方法本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法

3. 发明申请

WO2008041053A2 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 审中-公开
标题翻译： VEGF受体和HGF受体信号的抑制剂
公开(公告)号：WO2008041053A2
公开(公告)日：2008-04-10
申请号：PCT/IB2006004306
申请日：2006-05-19
申请人： METHYLGENE INC , SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
CPC分类号： C07D495/04
摘要： The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
摘要翻译：本发明涉及VEGF受体信号传导和HGF受体信号转导的抑制。本发明提供了用于抑制VEGF受体信号传导和HGF受体信号传导的化合物和方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法

4. 发明申请

WO2007054831A3 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 审中-公开
标题翻译： VEGF受体和HGF受体信号的抑制剂
公开(公告)号：WO2007054831A3
公开(公告)日：2007-10-04
申请号：PCT/IB2006003903
申请日：2006-05-19
申请人： METHYLGENE INC , SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY Z , ISAKOVIC LJUBOMIR
IPC分类号： C07D495/04 , A61K31/4365 , A61P35/00 , C07D487/04
CPC分类号： C07D495/04 , A61K31/519 , A61K31/522
摘要： The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling The invention provides compound A and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. Formula (A).
摘要翻译：本发明涉及血管内皮生长因子（VEGF）受体信号传导和肝细胞生长因子（HGF）受体信号传导的抑制本发明提供化合物A和抑制VEGF受体信号传导和HGF受体信号传导的方法。本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。式（A）。

5. 发明公开

EP1957498A4 INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 有权转让
标题翻译： VEGF和HGF受体信号传导抑制剂
公开(公告)号：EP1957498A4
公开(公告)日：2010-10-27
申请号：EP06851548
申请日：2006-05-19
申请人： METHYLGENE INC
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NAOMY
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P35/00
CPC分类号： C07D495/04

6. 发明专利

CA2611370C INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 未知
公开(公告)号：CA2611370C
公开(公告)日：2014-11-25
申请号：CA2611370
申请日：2006-05-19
申请人： METHYLGENE INC
发明人： SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , ZHAN LIJIE , RAEPPEL FRANCK , VAISBURG ARKADII , RAEPPEL STEPHANE , DEZIEL ROBERT , MANNION MICHAEL , ZHOU NANCY , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR , WAHHAB AMAL , GRANGER MARIE-CLAUDE , BERNSTEIN NOEMY
IPC分类号： C07D495/04 , A61K31/4365 , A61P35/00
摘要： The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

7. 发明专利

CA2573538C INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING 未知
公开(公告)号：CA2573538C
公开(公告)日：2014-11-25
申请号：CA2573538
申请日：2005-07-28
申请人： METHYLGENE INC
发明人： VAISBURG ARKADII , WILLIAM STEPHEN CLARIDGE , RAEPPEL FRANCK , SAAVEDRA OSCAR MARIO , BERNSTEIN NOEMY , GRANGER MARIE-CLAUDE , ZHAN LIJIE
IPC分类号： C07D495/04 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/55 , A61P35/00 , C07D487/04 , C07D491/04 , C07D498/04 , C07D513/04
摘要： The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

8. 发明专利

ES2438017T3 Inhibidores de la señalización del receptor del VEGF y del receptor del HGF 未知
公开(公告)号：ES2438017T3
公开(公告)日：2014-01-15
申请号：ES05770304
申请日：2005-07-28
申请人： METHYLGENE INC
发明人： VAISBURG ARKADII , WILLIAM STEPHEN , RAEPPEL FRANCK , SAAVEDRA OSCAR MARIO , BERSTEIN NAOMY , GRANGER MARIE-CLAUDE , ZHAN LIJIE
IPC分类号： C07D495/04 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/55 , A61P35/00 , C07D487/04 , C07D491/04 , C07D498/04 , C07D513/04
摘要： Un compuesto de la fórmula (A), que es un inhibidor de la señalización del receptor del VEGF y la señalización delreceptor del HGF:**Fórmula** y sales farmacéuticamente aceptables y complejos del mismo, en la que: T se selecciona del grupo que consiste en arilalquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, donde cada uno dedichos arilalquilo, cicloalquilo, heterociclilo, arilo y heteroarilo está opcionalmente sustituido con 1 a 3 R20seleccionados independientemente cada R20 se selecciona independientemente del grupo que consiste en -H, halógeno, trihalometilo, -CN, -NO2, -NH2, -OR17, -OCF3, -NR17R18, -S(O)0-2R17, -S(O)2NR17R17, -C(O)OR17, -C(O)NR17R17, -N(R17)SO2R17, -N(R17)C(O)R17, -N(R17)C(O)OR17, -C(O)R17, -C(O)SR17, alcoxi C1-C4, alquiltio C1-C4, -O(CH2)narilo, -O(CH2)nheteroarilo, -(CH2)0-5(arilo), -(CH2)0-5(heteroarilo), alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, -CH2(CH2)0-4-T2, un alquilcarbonilo C1-C4opcionalmente sustituido, alcoxi C1-C4, un amino opcionalmente sustituido con alquilo C1-C4 opcionalmentesustituido con alcoxi C1-C4 y un grupo carbocíclico o heterocíclico de tres a siete miembros saturado o insaturado,donde T2 se selecciona del grupo que consiste en -OH, -OMe, -OEt, -NH2, -NHMe, -NMe2, -NHEt y -NEt2, y donde elarilo, heteroarilo, alquilo C1-C6, alquenilo C2-C6 y alquinilo C2-C6 están opcionalmente sustituidos; W se selecciona del grupo que consiste en O, S, NH y NMe; Z se selecciona del grupo que consiste en O, o S y NH; X y X1 se seleccionan independientemente del grupo que consiste en H, alquilo C1-C6, halo, ciano, o nitro, donde elalquilo C1-C6 está opcionalmente sustituido, o X y X1, tomados junto con el átomo al que están unidos, forman un cicloalquilo C3-C7; R1, R2, R3 y R4 representan independientemente hidrógeno, halo, trihalometilo, -CN, -NO2, -NH2, -OR17, -NR17R18, -C(O)OR17, -C(O)R17, alcoxi C1-C4, alquiltio C1-C4, alquilo C1-C6, alquenilo C2-C6 o alquinilo C2-C6, donde el alquiloC1-C6, alquenilo C2-C6 y alquinilo C2-C6 están opcionalmente sustituidos; R17 se selecciona del grupo que consiste en H y R18.

9. 发明专利

AU2009221583B2 Inhibitors of protein tyrosine kinase activity 未知
公开(公告)号：AU2009221583B2
公开(公告)日：2013-06-20
申请号：AU2009221583
申请日：2009-02-27
申请人： METHYLGENE INC
发明人： ZHAN LIJIE , KISHIDA MASASHI , SAAVEDRA OSCAR MARIO , CLARIDGE STEPHEN WILLIAM , MANNION MICHAEL , UNO TETSUYUKI , RAEPPEL STEPHANE , VAISBURG ARKADII , GAUDETTE FREDERIC , ISAKOVIC LJUBOMIR
IPC分类号： C07D495/04 , A61K31/4365
摘要： This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

10. 发明专利

CA2763168A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY 未知
公开(公告)号：CA2763168A1
公开(公告)日：2009-09-11
申请号：CA2763168
申请日：2009-02-27
申请人： METHYLGENE INC
发明人： MANNION MICHAEL , RAEPPEL STEPHANE , CLARIDGE STEPHEN WILLIAM , GAUDETTE FREDERIC , ZHAN LIJIE , ISAKOVIC LJUBOMIR , SAAVEDRA OSCAR MARIO , UNO TETSUYUKI , KISHIDA MASASHI , VAISBURG ARKADII
IPC分类号： C07D495/04
摘要： This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式